Keywords: novartis, exforge, nda, accepted, review, fda, high-blood

Novartis' Exforge NDA accepted for review by FDA as high-blood pressure treatment option

Article | 08 May 2006

Print This

Swiss drug major Novartis says that a New Drug Application relating to the drug Exforge (amlodipine and valsartan) was accepted ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in